Physician profile
Joseph Scamardo
NPI 1639285489
$2,476.82
in general payments reported to CMS, 2019-2025
22 companies · $16.53 in 2025
The $16.53 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $831 · 2020: $406 · 2021: $40.32 · 2022: $647 · 2023: $536 · 2025: $16.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $552.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $486.28 | 2019-2023 | Oxtellar Xr |
| Abbvie INC. | $389.69 | 2022-2023 | Ubrelvy, Qulipta |
| Emd Serono, INC. | $255.99 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $203.16 | 2022 | |
| Amgen INC. | $187.05 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $183.93 | 2019-2023 | Austedo, Austedo Xr |
| Lilly USA, LLC | $152.35 | 2019-2023 | Amyvid |
| Allergan, INC. | $90.64 | 2019-2020 | |
| Corium, LLC | $86.72 | 2023 | Adlarity |
| Pfizer INC. | $84.88 | 2023 | |
| Amneal Pharmaceuticals LLC | $69.94 | 2019-2022 | |
| Sk Life Science, INC. | $57.00 | 2022-2023 | |
| Avanir Pharmaceuticals, INC. | $38.51 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $31.75 | 2022 | |
| Eisai INC. | $29.46 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $29.11 | 2021 | |
| Neurocrine Biosciences, INC. | $18.28 | 2022 | |
| Greenwich Biosciences, INC. | $18.15 | 2019 | |
| Genentech USA, INC. | $16.56 | 2019 | |
| Axsome Therapeutics, INC. | $16.53 | 2025 | Symbravo |
| Otsuka America Pharmaceutical, INC. | $15.58 | 2023 | Rexulti |
| Ucb, INC. | $15.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Scamardo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.